European Journal of Cardiovascular Medicine

gery and interventional cardiology for almost one decade. With preclinical studies showing prom- today in the setting of ischemic heart disease has been rather modest. However, clinical studies per- completion of ongoing phase III trials is mandatory. The following article repeats preclinical and clinical prerequisites for cardiac stem cell application and introduces the German Phase III PERindo- pril Function of the Endothelium in Coronary artery disease Trial (PERFECT) for intramyocardial stem cell injection in combination with CABG surgery.